Company Overview of Karolinska Institutet
Karolinska Institutet is a Swedish university, which specializes in medicine. Several companies in the field of medicine and biotechnology have been founded as a result of the university's research programmes. As a result, Karolinska Institutet cooperates closely with the private sector and has created an investment arm (Karolinska Investment Fund) in order to enhance its scientists' innovations. Founded in 1810, the company is headquartered in Stockholm.
Founded in 1810
46 8 728 64 00
46 8 31 11 01
Key Executives for Karolinska Institutet
Professor of Environmental Toxicology
Professor of Pharmacology
Professor of Neurobiology
Compensation as of Fiscal Year 2015.
Karolinska Institutet Key Developments
Immunicum AB (publ) with Karolinska Institute and Karolinska University Hospital Submit an Application for Starting a Clinical Study with INTUVAX in GIST
Sep 17 15
Immunicum AB (publ) announced that it, together with Karolinska Institute and Karolinska University Hospital, has filed an application with the Swedish Medical Products Agency to start a phase I/II study with the company's therapeutic cancer immune primer INTUVAX®. The safety and efficacy of INTUVAX® in combination with sunitinib in patients with incurable Gastrointestinal Stromal Tumor (GIST) will be examined. The first observations of INTUVAX® in humans looks promising and have made research group wanting to look closely at INTUVAX’s effect on critically ill GIST patients. The study is expected to start at the end of the year and will be conducted at the Karolinska University Hospital during about a year. This is the fourth clinical study with INTUVAX®. The company's most advanced clinical trial is an ongoing phase II study in patients with metastatic renal cell cancer (mRCC). Immunicum also has an ongoing phase I/II study in patients with primary liver cancer and a completed phase I/II study in mRCC where the Company continues to follow overall survival. Up to 12 patients with GIST, showing signs of progression with established second-line treatment with sunitinib (Sutent®, Pfizer) will be included in the study. The patients will obtain two or three doses of INTUVAX. The study design gives Immunicum the opportunity to compare the effect of two and three vaccine doses (for the first six respectively the last six patients in the study). Since Immunicum’s completed phase I/II study in patients with metastatic renal cell carcinoma, including patients with so-called sarcomatoid tumor development, showed signs of synergy between INTUVAX and sunitinib, the GIST patients who progress despite ongoing treatment with sunitinib will remain on sunitinib treatment during at least three months. The study's primary objective is to determine safety and the most important secondary objective is to study whether patients showing progression and resistance to existing treatment after INTUVAX treatment show objective tumor response. Immunicum expects the company's existing cash to cover the financing of the GIST study and that the study will not affect the timing of a potential future fundraising.
Moderna to Collaborate with Karolinska Institutet and Karolinska University Hospital on Discovery of New Messenger RNA Therapeutics™
Oct 16 14
Moderna Therapeutics announced a strategic, long-term collaboration with Karolinska Institutet (KI) and Karolinska University Hospital (KUH) for the discovery and development of innovative drugs using Moderna's messenger RNA (mRNA) Therapeutics™ technology. mRNA Therapeutics™ enable the in vivo production of both intracellular proteins and secreted proteins. As a result, Moderna's platform has the potential to speed the development and manufacture of treatments for many diseases that are currently untreatable with existing pharmaceutical approaches. Under the terms of the partnership, Moderna will sponsor research grants for scientists at both institutions to conduct preclinical research with novel mRNA Therapeutics™. As this pre-clinical work is successfully completed, Moderna will conduct clinical trials of new drug candidates at Karolinska University Hospital. To solidify the scientific and clinical collaboration between the organizations, and to optimize the output of this important partnership, Moderna is creating a new laboratory in Stockholm, Sweden, located in the Novum building next to the Karolinska University Hospital Huddinge campus.
Karolinska Institutet Presents at Swedish-American Life Science Summit 2014, Aug-21-2014 02:00 PM
Aug 21 14
Karolinska Institutet Presents at Swedish-American Life Science Summit 2014, Aug-21-2014 02:00 PM. Venue: EY Headquarters, Stockholm, Sweden. Speakers: Anders Hamsten, President.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|